Tactile Medical Raises 2026 Revenue Guidance Amid Medicare Changes
Tactile Systems Technology has increased its 2026 revenue projections to between $360 million and $368 million, reflecting strong operational momentum and improving market conditions. The company reported impressive 23% revenue growth during the first quarter of 2026, demonstrating robust demand for its lymphedema and chronic venous insufficiency treatment devices.
A significant factor driving this optimistic outlook is the maturing Medicare prior authorization process. Previously, authorization delays created uncertainty for healthcare providers and patients seeking access to Tactile's therapies. As this administrative process has stabilized, hospitals and clinics can now plan treatments more efficiently, removing a major friction point that had previously constrained sales growth.
MA
Tuesday, May 5, 2026 at 10:40 AM
0
0
1
3